State Street Corp Has $23.66 Million Stock Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

State Street Corp increased its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 65.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,790,707 shares of the company’s stock after acquiring an additional 707,409 shares during the quarter. State Street Corp owned about 1.11% of Neumora Therapeutics worth $23,655,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Amalgamated Bank increased its position in shares of Neumora Therapeutics by 472.8% during the second quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock worth $29,000 after buying an additional 2,402 shares during the period. Quarry LP acquired a new stake in Neumora Therapeutics during the 2nd quarter worth about $98,000. SkyOak Wealth LLC bought a new position in shares of Neumora Therapeutics in the 2nd quarter worth about $147,000. Principal Financial Group Inc. acquired a new position in shares of Neumora Therapeutics in the 2nd quarter valued at about $166,000. Finally, Intech Investment Management LLC acquired a new position in shares of Neumora Therapeutics in the 3rd quarter valued at about $175,000. 47.65% of the stock is currently owned by institutional investors.

Neumora Therapeutics Price Performance

Shares of NASDAQ NMRA opened at $10.85 on Monday. The company has a 50-day moving average price of $11.61 and a 200-day moving average price of $11.54. The stock has a market capitalization of $1.75 billion, a P/E ratio of -5.80 and a beta of 3.34. Neumora Therapeutics, Inc. has a 1 year low of $8.33 and a 1 year high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same period in the previous year, the company earned ($1.14) earnings per share. As a group, equities research analysts anticipate that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Insider Activity at Neumora Therapeutics

In other Neumora Therapeutics news, insider Robert A. Lenz sold 5,563 shares of the stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total transaction of $83,500.63. Following the completion of the transaction, the insider now owns 322,966 shares in the company, valued at $4,847,719.66. This trade represents a 1.69 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Matthew K. Fust sold 14,049 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $17.03, for a total transaction of $239,254.47. Following the completion of the sale, the director now directly owns 20,100 shares in the company, valued at approximately $342,303. This trade represents a 41.14 % decrease in their position. The disclosure for this sale can be found here. 26.40% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Royal Bank of Canada reissued an “outperform” rating and issued a $29.00 price target on shares of Neumora Therapeutics in a research note on Friday, November 22nd. Needham & Company LLC reissued a “buy” rating and set a $23.00 target price on shares of Neumora Therapeutics in a research note on Wednesday, November 13th. JPMorgan Chase & Co. downgraded shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $18.00 to $15.00 in a research note on Tuesday, November 5th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Neumora Therapeutics in a research report on Monday, December 16th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $23.40.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.